Of note, they observed high levels of TIL ‘exhaustion markers’ such as PD-1 and LAG-3 post infusion, as well as increased expression of MHC-II and PD-L1 in the tumour tissue, which may be impeding the efficacy of the treatment. The gene discussed is CD274; the disease is neoplasm.